Cellumed, Bio Sector Demand Surges... Expansion Nears Completion

Cellumed is expanding its production facilities as demand for DBM, dental powder, and other products surges. On the 12th, the company announced that the high-intensity expansion capable of more than doubling the production volume of core products is in its final stages.

From the second half of this year, when the effects of the expansion become fully realized, it is expected that performance will improve, focusing on the core bio business. The expansion focuses on increasing product manufacturing capacity through ▲ the establishment of a dedicated production line for allogeneic dermis ▲ the expansion of the dental bone graft production line ▲ the introduction of automation equipment.

Allogeneic dermis is dermal tissue manufactured by processing donated human skin and is mainly used in women's medicine and men's medicine fields such as breast reconstruction. Cellumed has been developing allogeneic dermal tissue since 2021. From July to August this year, full-scale mass production and sales are planned to begin through the newly established dedicated production line.

Dental bone graft material is a bio-material used to fill bone defects in the area of extracted teeth for implants. Cellumed produces and sells allogeneic bone graft materials.

Cellumed plans to expand the customer base for the profitable allogeneic dermis products beyond men's medicine to orthopedics and burn surgery, and expects sales of these products to more than double next year. The company also explained that the expansion of dental bone graft production will be completed within this year, and significant growth in both sales and profitability is expected next year.

Kang Yong-joo, Vice President of Cellumed, said, "Due to the expansion to meet increased demand and market growth for existing core products, a temporary supply adjustment is expected to cause a decrease in sales in the bio business sector in the first half of this year." He added, "From the second half of this year, as the effects of the expansion become fully realized, sales growth and performance improvement in the bio business sector are expected."

He continued, "The key development product ‘BMP2’ is smoothly progressing through the approval process required by the Ministry of Food and Drug Safety for clinical trials in collaboration with Seoul National University Hospital and others," emphasizing, "The mRNA production enzyme has also been successfully developed with a German company, and optimization work for sample manufacturing is underway, indicating that the overall bio business is progressing smoothly."

This content was produced with the assistance of AI translation services.